GlaxoSmithKline PLC
23 November 2003
US Court of Appeals Rules in Augmentin Patent Case
LONDON, November 21, 2003 -- GlaxoSmithKline (GSK) today announced that the US
Court of Appeals for the Federal Circuit in Washington, DC has ruled in favour
of Geneva Pharmaceuticals, Teva Pharmaceuticals and Ranbaxy, and upheld lower
court rulings that invalidated GSK's US patents for its antibiotic Augmentin.
GSK continues to be committed to its newer Augmentin antibiotic medicines --
Augmentin ES and XR-- which now represent nearly 35% of the total number of
prescriptions being written for branded and generic Augmentin.
S M Bicknell
Company Secretary
21st November 2003
About GSK:
GlaxoSmithKline, one of the world's leading research-based pharmaceutical and
healthcare companies, is committed to improving the quality of human life by
enabling people to do more, feel better and live longer. For more information,
please visit the company's web site at www.gsk.com.
Inquiries:
US Media Inquiries: Nancy Pekarek (215) 751 7709
Mary Anne Rhyne (919) 483 2839
Patricia Seif (215) 751 7709
UK Media Inquiries: Martin Sutton (020) 8047 5502
Chris Hunter-Ward (020) 8047 5502
David Mawdsley (020) 8047 5502
European Analyst/
Investor enquiries: Duncan Learmouth (020) 8047 5540
Anita Kidgell (020) 8047 5542
Philip Thomson (020) 8047 5543
US Analyst/ Investor enquiries: Frank Murdolo (215) 751 7002
Tom Curry (215) 751 5419
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.